Catalyst Pharmaceutical
CPRX
316 hedge funds and large institutions have $1.9B invested in Catalyst Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 98 increasing their positions, 105 reducing their positions, and 21 closing their positions.
219% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 21
27% more capital invested
Capital invested by funds: $1.5B → $1.9B (+$398M)
17% more funds holding
Funds holding: 271 → 316 (+45)
7% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 105
1.58% less ownership
Funds ownership: 82.06% → 80.48% (-1.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
61% less call options, than puts
Call options by funds: $610K | Put options by funds: $1.58M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$15M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.98M |
| 3 |
Millennium Management
New York
|
+$7.97M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$7.78M |
| 5 |
Goldman Sachs
New York
|
+$7.12M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$53.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$33.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.3M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.78M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.58M |
CPRX Hedge Fund Activity: Q3 2024 in Review
316 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2024, worth a combined $1.9B — up 27% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new CPRX positions and 21 closed out — a net gain of 46 holders — while 98 added to existing stakes and 105 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $15M. The largest seller was Deerfield Management, cutting an estimated $53.7M.
- 316 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2024, up from 271 in Q2 2024.
- Funds reported $1.9B of Catalyst Pharmaceutical stock for Q3 2024, up 27% quarter-over-quarter.
- 67 funds opened new Catalyst Pharmaceutical positions in Q3 2024 and 21 closed out, a net change of +46 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2024 was Morgan Stanley, an estimated $15M added.
- The largest Catalyst Pharmaceutical seller in Q3 2024 was Deerfield Management, an estimated $53.7M sold.
Based on aggregated 13F filings for Q3 2024.